Simona Gasparro
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.
Journal: NPJ breast cancer
Published: January 23, 2026
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.
Journal: ESMO open
Published: April 01, 2024
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: August 16, 2022
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.
Journal: Molecular cancer
Published: April 30, 2021
Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.
Journal: Future oncology (London, England)
Published: June 06, 2020
Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?
Journal: Oncology
Published: July 25, 2018
Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.
Journal: In vivo (Athens, Greece)
Published: March 15, 2018
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
Journal: Future oncology (London, England)
Published: November 29, 2017
Showing 1-12 of 12
Last Updated: 09/26/2026